Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $43.3750.

Several brokerages have issued reports on VOR. Weiss Ratings raised shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday. Wedbush lifted their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th.

Trending Headlines about Vor Biopharma

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target to $27. The higher target provides additional support for the stock’s valuation and reflects continued optimism about Vor Biopharma’s long-term prospects. Wedbush Increases Vor Biopharma Price Target to $27.00
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $31 price target. The firm expects continued losses in the near term, including estimated 2027 EPS of negative $3.65, but projects a return to profitability by 2029 at $1.33 EPS. Its estimates imply that the investment case remains dependent on successful clinical and commercial execution.
• Negative Sentiment: HC Wainwright lowered several future earnings forecasts. The firm reduced its Q3 2026 EPS estimate to negative $0.91 from negative $0.70 and its Q4 2026 estimate to negative $0.94 from negative $0.72. It also cut full-year 2027 EPS to negative $3.65 from negative $2.78, full-year 2028 EPS to negative $2.61 from negative $1.67, and full-year 2029 EPS to $1.33 from $1.86. These revisions suggest higher expected losses and a slower path to profitability.
• Negative Sentiment: Recent quarterly results missed expectations. Vor reported a quarterly loss of $0.80 per share versus the consensus estimate of a $0.69 loss, an unfavorable earnings surprise that pressured the stock. Analysts expect the company to remain unprofitable during the current fiscal year. Vor Biopharma Stock Price Down Following Weak Earnings

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $36,000. Squarepoint Ops LLC purchased a new position in Vor Biopharma in the third quarter worth $230,000. Bank of America Corp DE lifted its holdings in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after acquiring an additional 4,144 shares during the period. BNP Paribas Financial Markets lifted its holdings in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after acquiring an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Vor Biopharma during the 3rd quarter worth $304,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Trading Down 1.1%

Shares of VOR stock opened at $23.03 on Friday. The business’s 50 day moving average is $18.55 and its two-hundred day moving average is $16.01. Vor Biopharma has a twelve month low of $6.50 and a twelve month high of $50.20.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, research analysts predict that Vor Biopharma will post -2.7 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).